Skip main navigation

Research & Development
Research & Development

Home > R&D > Licensing Activities > Our Partners

Skip side navigation

Main contents starts here

Recent Achievement Deals

Recent achievements in alliance activities are presented below.
The partners range from major domestic and overseas pharmaceutical companies to high-tech venture firms. We flexibly arrange role assignments with our partners on research, development and sales areas under discussions based on mutual trust.

Recent Achievements in In-licensing Activities

Licensor Product Name or Development Code Drug Class Territory Time
Indication(s)
Cell Genesys GVAX immunotherapy for prostate cancer   World Mar.08
Prostate Cancer
Japan Poliomyelitis Research Seed viruses for the Sabin-inactivated poliovirus vaccine   World Mar.08
Polio
Amgen VectibixTM, AMG706 etc.   Japan(VectibixTM etc.),
World (AMG706)
Feb.08
cancer etc.
Lundbeck Lu AA21004, Lu AA24530   US and Japan Sep.07
Mood and Anxiety disorders
Santhera Idebenone   EU Aug.07
Duchenne Muscular Dystrophy
CanBas CBP501 G2 checkpoint abrogation World Mar.07
cancer
Xenon XEN-401   Japan& Asia Sep.06
Pain
Affymax Hematide erythropoiesis - stimulating agent World except Japan Jun.06
anemia of chronic kidney disease (CKD) and cancer
Affymax Hematide erythropoiesis - stimulating agent Japan Feb.06
anemia of chronic kidney disease (CKD) and cancer
Pronova Biocare AS Omacor EPA/DHA Japan Nov.05
hypertriglyceridemia
Merck KGaA EMD72000 a humanized mAB targeting EGFR World Sep.05
cancer
Santhera Idebenone   US
EU
Aug.05
Friedreich's Ataxia
Toray Industries Inc TRK130   US
EU
Apr.05
Frequent urination/Urinary Incontinence
3M R851 Immune Response Modifier World Mar.05
Cervical high-risk human papillomavirus (HPV) infection and cervical dysplasia
Sucampo Pharmaceuticals SPI-0211  RU-0211 Chloride Channel Opener US
Canada
Oct.04
Constipation, Constipation - predominant Irritable Bowel Syndrome
Alizyme ATL-962 Lipase inhibitor Japan Jan.04
Obesity, Diabetes
Andrx Combination product of Actos and metformin extended release -- World Jan.04
Diabetes
Eli Lilly LY-333531 PKCβ inhibitor Japan Nov.03
Diabetic microvascular complications
Ajinomoto Benet Bone resorption inhibitor Japan May.02
Osteoporosis

Recent Achievements in Marketing Activities

Licensor Agreement Indication(s) or Classification Time
Cephalon Co-promotion of modafinil (Provigil) in U.S. Wake-promoting agent Jun.06
Wyeth/Wyeth Japan Co-promotion of etanercept (Enbrel in U.S.) in Japan Rheumatoid arthritis May.03
Kissei Pharmaceutical Co-marketing of short-acting postprandial hyperglycemia suppressant (Glufast) in Japan Antihyperglycemic agent Aug.02
Novo Nordisk Pharma Co-promotion of pioglitazone (Actos) in Japan Antihyperglycemic agent Aug.99

Page Top